Safety and efficacy of fremanezumab in real clinical practice in patients with chronic migraine

Objective : to evaluate the efficacy and safety of fremanezumab in patients with chronic migraine (CM) in real-life clinical practice. Material and methods . In a 12-week, open-label, prospective study, 27 patients (21 women and 6 men, mean age 41±10 years) with CM were administered with fremanezuma...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nevrologii͡a︡, neĭropsikhiatrii͡a︡, psikhosomatika neĭropsikhiatrii͡a︡, psikhosomatika, 2024-02, Vol.16 (1), p.65-70
Hauptverfasser: Belskaya, G. N., Krasnikov, A. V., Kiryanova, E. A., Prokopovich, M. E., Sakharova, E. V., Makarov, G. V.
Format: Artikel
Sprache:eng ; rus
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective : to evaluate the efficacy and safety of fremanezumab in patients with chronic migraine (CM) in real-life clinical practice. Material and methods . In a 12-week, open-label, prospective study, 27 patients (21 women and 6 men, mean age 41±10 years) with CM were administered with fremanezumab 225 mg subcutaneously monthly or 675 mg once (quarterly). We assessed changes in migraine attack intensity using a visual analogue scale (VAS), a reduction in the number of headache days per month by 50% or more, the impact of headache on daily activities (HIT-6 scale), adverse events (AEs) and tolerability of fremanezumab. Results . The number of migraine days per month decreased by 50% or more in 52%, 63% and 70% of patients at weeks 4, 8 and 12, respectively. In 26% of patients, the number of days with headaches was reduced by 75% or more by the end of the study. On average, the number of days with migraine decreased by 11.6 per month, with monthly injections – by 12.6 per month (p
ISSN:2074-2711
2310-1342
DOI:10.14412/2074-2711-2024-1-65-70